Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
MT-1 vs. Semaglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Both have FDA-approved products for defined, product-specific indications.
⇄ Different
Biggest Difference
MT-1 is distinguished by predominant MC1R agonist with strong evidence for one specific 16 mg implant in adult EPP. The regulated SCENESSE record does not validate powders, sprays, injections, or other products sold as MT-1; Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
MT-1 is distinguished in the current record by predominant MC1R agonist with strong evidence for one specific 16 mg implant in adult EPP. The regulated SCENESSE record does not validate powders, sprays, injections, or other products sold as MT-1. Semaglutide is distinguished by single GLP-1 receptor agonist with multiple approved injection and tablet products and mature outcomes evidence. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceSemaglutide
MT-1: Strong but product-specific. Semaglutide: Mature human evidence.
Regulatory historyComparable
MT-1: FDA approved only as the SCENESSE implant for adult EPP. Semaglutide: FDA approved for defined product-specific indications.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
MT-1
- Pain-free light exposure in adult EPP
- Phototoxic reactions and quality of life in EPP
- Skin pigmentation
- Vitiligo repigmentation with narrowband UV-B
Semaglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Chronic kidney disease
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
MT-1Narrow product approval
FDA approved only as SCENESSE to increase pain-free light exposure in adults with EPP. Cosmetic tanning, vitiligo, children, liver protection, and other MT-1 formulations are not approved uses.
SemaglutideFDA-labeled indications
FDA approved in product-specific formulations for defined weight-management, type 2 diabetes, cardiovascular, kidney, and MASH indications.
Evidence depthEvidence, not a winner
MT-1Controlled + real-world EPP
Two pivotal controlled EPP trials, current regulatory labeling, postauthorization cohorts of 117 and 200 patients, one small randomized vitiligo combination study, and observational liver and vitamin-D research.
SemaglutideMature Phase 3 + outcomes
Multiple large Phase 3 programs and outcomes trials, including SELECT, FLOW, ESSENCE, STEP TEENS, and the higher-dose STEP UP program.
Weight outcomesEvidence, not a winner
MT-1No dedicated evidence
No controlled human weight-management or body-composition outcome study was located.
SemaglutidePeer-reviewed Phase 3
STEP 1 reported −14.9% mean change at 68 weeks with 2.4 mg versus −2.4% placebo. STEP UP later reported −18.7% with 7.2 mg, −15.6% with 2.4 mg, and −3.9% with placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
MT-1No dedicated evidence
No controlled human glucose-control or diabetes-outcomes study was located.
SemaglutideApproved + extensive trials
Approved injection and oral products have extensive type 2 diabetes evidence. Product names, routes, strengths, and label instructions are not automatically interchangeable.
Obstructive sleep apnoeaEvidence, not a winner
MT-1No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
SemaglutideNo approved indication
No FDA-approved semaglutide indication for obstructive sleep apnoea was identified in the current U.S. labels.
Cardiovascular outcomesEvidence, not a winner
MT-1No outcomes program
No cardiovascular outcomes program was located. The current label reports serious postmarketing hypersensitivity, including anaphylaxis, and recommends product-specific monitoring.
SemaglutideSELECT + labeled uses
SELECT demonstrated fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. Other approved product labels cover defined diabetes populations.
Administration and handlingEvidence, not a winner
MT-1SCENESSE implant label only
The FDA label describes a clinician-placed 16 mg bioresorbable implant every two months for adult EPP. It is not self-injection or reconstitution guidance for other MT-1 products.
SemaglutideMultiple product-specific labels
Current FDA labels include weekly subcutaneous injections and daily oral tablets with product-specific administration, switching, and storage instructions. Approved products require no reconstitution.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Long-term rare safety, pigmentary surveillance, pediatric use, off-label skin indications, liver outcomes, and whether any implant findings apply to unapproved formulations.
- Long-term comparative outcomes across newer products and doses, rare events at population scale, and evidence outside studied populations or approved products.
Community Intelligence
Emerging patterns, clearly separated from evidence
MT-1
No community experiences yetBe the first account holder to contribute.
Semaglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.